IQVIA Reports Third-Quarter 2022 Results

IQVIA Reports Third-Quarter 2022 Results




IQVIA Reports Third-Quarter 2022 Results

  • Revenue of $3,562 million grew 5.0 percent year-over-year on a reported basis and 10.5 percent at constant currency
  • GAAP Net Income of $283 million grew 8.4 percent year-over-year
  • Adjusted EBITDA of $814 million increased 11.8 percent year-over-year
  • GAAP Diluted Earnings per Share of $1.49 grew 11.2 percent year-over-year
  • Adjusted Diluted Earnings per Share of $2.48 increased 14.3 percent year-over-year
  • R&D Solutions quarterly bookings of over $2.5 billion; excluding pass throughs, quarterly bookings at a historic high of over $2.0 billion, representing a services book-to-bill ratio of 1.39x
  • R&D Solutions contracted backlog of $25.8 billion grew 5.4 percent year-over-year and 9.4 percent excluding the impact of foreign exchange

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2022.

Third-Quarter 2022 Operating Results

Revenue for the third quarter of $3,562 million increased 5.0 percent on a reported basis and 10.5 percent at constant currency, compared to the third quarter of 2021. Technology & Analytics Solutions (TAS) revenue of $1,400 million grew 4.7 percent on a reported basis and 11.6 percent at constant currency. Research & Development Solutions (R&DS) revenue of $1,979 million increased 6.8 percent on a reported basis and 10.7 percent at constant currency. Excluding the impact of pass throughs, R&DS revenue grew 7.4 percent year-over-year on a reported basis. Contract Sales & Medical Solutions (CSMS) revenue of $183 million decreased 9.0 percent on a reported basis and grew 1.0 percent at constant currency.

As of September 30, 2022, R&DS contracted backlog, including reimbursed expenses, was $25.8 billion, growing 5.4 percent year-over-year and 9.4 percent excluding foreign exchange. The company expects approximately $7.1 billion of this backlog to convert to revenue in the next twelve months. R&D Solutions quarterly bookings exceeded $2.5 billion and excluding pass throughs were at a historic high of over $2.0 billion. The third-quarter book-to-bill ratio was 1.39x excluding reimbursed expenses and 1.27x including reimbursed expenses. For the twelve months ended September 30, 2022, the book-to-bill ratio was 1.35x excluding reimbursed expenses and 1.29x including reimbursed expenses.

“IQVIA had another outstanding quarter of operational and financial performance,” said Ari Bousbib, chairman and CEO of IQVIA. “Each of our business segments delivered impressive organic revenue growth at constant currency, we increased adjusted diluted earnings per share by over 14 percent, and free cash flow generation was very strong. Despite the global macro environment, demand for IQVIA services and offerings continues to be strong across both the commercial and the clinical portfolios, with R&DS delivering over $2 billion of services bookings for the first time ever.”

Third-quarter GAAP Net Income was $283 million, up 8.4 percent year-over-year, and GAAP Diluted Earnings per Share was $1.49, an increase of 11.2 percent year-over-year. Adjusted Net Income was $470 million, up 11.1 percent year-over-year, and Adjusted Diluted Earnings per Share was $2.48, up 14.3 percent year-over-year. Adjusted EBITDA was $814 million, increasing 11.8 percent year-over-year.

Year-to-Date 2022 Operating Results

Revenue for the first nine months of 2022 was $10,671 million, up 4.2 percent on a reported basis and 8.1 percent at constant currency compared to the first nine months of 2021. TAS revenue was $4,247 million, representing growth of 5.2 percent reported and 10.3 percent at constant currency. R&DS revenue was $5,863 million, up 4.5 percent on a reported basis and 7.1 percent at constant currency. CSMS revenue was $561 million, down 4.6 percent on a reported basis and up 2.9 percent at constant currency.

GAAP Net Income for the first nine months of 2022 was $864 million, up 33.3 percent year-over-year and GAAP Diluted Earnings per Share was $4.52, up 36.1 percent year-over-year. Adjusted Net Income was $1,413 million for the first nine months of 2022, increasing 11.8 percent year-over-year, and Adjusted Diluted Earnings per Share was $7.39, up 14.0 percent year-over-year. Adjusted EBITDA for the first nine months of 2022 was $2,426 million, up 10.6 percent year-over-year.

Financial Position

As of September 30, 2022, cash and cash equivalents were $1,274 million and debt was $12,394 million, resulting in net debt of $11,120 million. IQVIA’s Net Leverage Ratio was 3.4x trailing twelve-month Adjusted EBITDA. For the third quarter of 2022, Operating Cash Flow was $863 million and Free Cash Flow was $698 million. For the first nine months of 2022, Operating Cash Flow was $1,700 million and Free Cash Flow was $1,197 million.

Share Repurchase

During the third quarter of 2022, the company repurchased $150 million of its common stock, bringing year-to-date share repurchase activity to $1,143 million. IQVIA had $1,380 million of share repurchase authorization remaining as of September 30, 2022.

Full-Year 2022 Guidance

For the full year of 2022, the company continues to expect low-to-mid teens organic revenue growth at constant currency, excluding COVID-related work. To reflect primarily the impact of the strengthening US dollar and to a lesser extent, minor delays in the timing of certain trial deliveries due to external macro factors, the company is updating its full-year 2022 revenue guidance range assuming foreign exchange currency rates as of October 24, 2022. The company now expects revenue to be between $14,325 million and $14,425 million, representing growth of 7.4 to 8.2 percent at constant currency, and 3.2 to 4.0 percent on a reported basis. The company is also updating its Adjusted EBITDA guidance range to be $3,330 million to $3,360 million, representing growth of 10.2 to 11.2 percent. Additionally, the company is raising Adjusted Diluted Earnings per Share by 5 cents at the midpoint. Adjusted Diluted Earnings per Share is expected to be between $10.10 to $10.20, up 11.8 to 13.0 percent on a reported basis.

Fourth-Quarter 2022 Guidance

For the fourth quarter of 2022, the company expects revenue to be between $3,654 million and $3,754 million, representing growth of 5.5 to 8.2 percent at constant currency and 0.5 to 3.2 percent on a reported basis, with underlying constant currency organic growth excluding COVID-related work of over 10 percent at the midpoint. The company expects Adjusted EBITDA to be between $904 million and $934 million and Adjusted Diluted Earnings per Share to be between $2.72 and $2.82, representing growth of 9.2 to 12.8 percent and 6.7 to 10.6 percent on a reported basis, respectively.

All financial guidance assumes foreign currency exchange rates as of October 24, 2022 remain in effect for the forecast period.

Webcast & Conference Call Details

IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its third-quarter 2022 results and its fourth-quarter and full-year 2022 guidance. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants connect to the call using the information provided in the confirmation email and will be placed directly into the call.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 85,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behavior and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our fourth-quarter and full-year 2022 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, international conflicts or other disruptions outside of our control such as the current situation in Ukraine and Russia; our ability to accurately model or forecast the impact of the spread and/or containment of COVID-19, including any variants, among other sources of business interruption, on our operations and financial results; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; government regulators or our customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions, inflation, and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to our business, see the “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”), as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Note on Non-GAAP Financial Measures

This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States (“GAAP”), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, the Company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements and trademarks, trade names and other from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income attributable to IQVIA Holdings Inc. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. Our fourth-quarter and full-year 2022 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based compensation and other items not reflective of the company’s ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP.

IQVIAFIN

 
 
 

Table 1

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(preliminary and unaudited)

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

(in millions, except per share data)

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Revenues

 

$

3,562

 

 

$

3,391

 

 

$

10,671

 

 

$

10,238

 

Cost of revenues, exclusive of depreciation and amortization

 

 

2,321

 

 

 

2,253

 

 

 

6,975

 

 

 

6,869

 

Selling, general and administrative expenses

 

 

517

 

 

 

498

 

 

 

1,488

 

 

 

1,422

 

Depreciation and amortization

 

 

248

 

 

 

336

 

 

 

773

 

 

 

1,002

 

Restructuring costs

 

 

4

 

 

 

2

 

 

 

15

 

 

 

15

 

Income from operations

 

 

472

 

 

 

302

 

 

 

1,420

 

 

 

930

 

Interest income

 

 

(4

)

 

 

(2

)

 

 

(7

)

 

 

(4

)

Interest expense

 

 

108

 

 

 

92

 

 

 

288

 

 

 

285

 

Loss on extinguishment of debt

 

 

 

 

 

1

 

 

 

 

 

 

25

 

Other expense (income), net

 

 

8

 

 

 

(62

)

 

 

51

 

 

 

(128

)

Income before income taxes and equity in (losses) earnings of unconsolidated affiliates

 

 

360

 

 

 

273

 

 

 

1,088

 

 

 

752

 

Income tax expense

 

 

70

 

 

 

12

 

 

 

212

 

 

 

104

 

Income before equity in (losses) earnings of unconsolidated affiliates

 

 

290

 

 

 

261

 

 

 

876

 

 

 

648

 

Equity in (losses) earnings of unconsolidated affiliates

 

 

(7

)

 

 

 

 

 

(12

)

 

 

5

 

Net income

 

 

283

 

 

 

261

 

 

 

864

 

 

 

653

 

Net income attributable to non-controlling interests

 

 

 

 

 

 

 

 

 

 

 

(5

)

Net income attributable to IQVIA Holdings Inc.

 

$

283

 

 

$

261

 

 

$

864

 

 

$

648

 

Earnings per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic

 

$

1.52

 

 

$

1.36

 

 

$

4.59

 

 

$

3.38

 

Diluted

 

$

1.49

 

 

$

1.34

 

 

$

4.52

 

 

$

3.32

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

Basic

 

 

186.5

 

 

 

191.5

 

 

 

188.3

 

 

 

191.5

 

Diluted

 

 

189.4

 

 

 

195.3

 

 

 

191.3

 

 

 

195.0

 

 
 
 

Table 2

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(preliminary and unaudited)

 

(in millions, except per share data)

 

September 30, 2022

 

December 31, 2021

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

1,274

 

 

$

1,366

 

Trade accounts receivable and unbilled services, net

 

 

2,640

 

 

 

2,551

 

Prepaid expenses

 

 

176

 

 

 

156

 

Income taxes receivable

 

 

47

 

 

 

58

 

Investments in debt, equity and other securities

 

 

87

 

 

 

111

 

Other current assets and receivables

 

 

528

 

 

 

521

 

Total current assets

 

 

4,752

 

 

 

4,763

 

Property and equipment, net

 

 

507

 

 

 

497

 

Operating lease right-of-use assets

 

 

333

 

 

 

406

 

Investments in debt, equity and other securities

 

 

64

 

 

 

76

 

Investments in unconsolidated affiliates

 

 

87

 

 

 

88

 

Goodwill

 

 

13,177

 

 

 

13,301

 

Other identifiable intangibles, net

 

 

4,718

 

 

 

4,943

 

Deferred income taxes

 

 

97

 

 

 

124

 

Deposits and other assets

 

 

488

 

 

 

491

 

Total assets

 

$

24,223

 

 

$

24,689

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable and accrued expenses

 

$

2,971

 

 

$

2,981

 

Unearned income

 

 

1,842

 

 

 

1,825

 

Income taxes payable

 

 

124

 

 

 

137

 

Current portion of long-term debt

 

 

151

 

 

 

91

 

Other current liabilities

 

 

165

 

 

 

207

 

Total current liabilities

 

 

5,253

 

 

 

5,241

 

Long-term debt, less current portion

 

 

12,243

 

 

 

12,034

 

Deferred income taxes

 

 

560

 

 

 

410

 

Operating lease liabilities

 

 

259

 

 

 

313

 

Other liabilities

 

 

561

 

 

 

649

 

Total liabilities

 

 

18,876

 

 

 

18,647

 

Commitments and contingencies

 

 

 

 

Stockholders’ equity:

 

 

 

 

Common stock and additional paid-in capital, 400.0 shares authorized as of September 30, 2022 and December 31, 2021, $0.01 par value, 256.3 shares issued and 185.8 shares outstanding as of September 30, 2022; 255.8 shares issued and 190.6 shares outstanding as of December 31, 2021

 

 

10,853

 

 

 

10,777

 

Retained earnings

 

 

3,107

 

 

 

2,243

 

Treasury stock, at cost, 70.5 and 65.2 shares as of September 30, 2022 and December 31, 2021, respectively

 

 

(7,715

)

 

 

(6,572

)

Accumulated other comprehensive loss

 

 

(898

)

 

 

(406

)

Total stockholders’ equity

 

 

5,347

 

 

 

6,042

 

Total liabilities and stockholders’ equity

 

$

24,223

 

 

$

24,689

 

 
 
 

Table 3

IQVIA HOLDINGS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(preliminary and unaudited) 

 

 

 

Nine Months Ended September 30,

(in millions)

 

 

2022

 

 

 

2021

 

Operating activities:

 

 

 

 

Net income

 

$

864

 

 

$

653

 

Adjustments to reconcile net income to cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

 

773

 

 

 

1,002

 

Amortization of debt issuance costs and discount

 

 

11

 

 

 

14

 

Stock-based compensation

 

 

136

 

 

 

128

 

Losses (earnings) from unconsolidated affiliates

 

 

12

 

 

 

(5

)

Loss (gain) on investments, net

 

 

35

 

 

 

(9

)

Benefit from deferred income taxes

 

 

(52

)

 

 

(83

)

Changes in operating assets and liabilities:

 

 

 

 

Change in accounts receivable, unbilled services and unearned income

 

 

(88

)

 

 

663

 

Change in other operating assets and liabilities

 

 

9

 

 

 

(113

)

Net cash provided by operating activities

 

 

1,700

 

 

 

2,250

 

Investing activities:

 

 

 

 

Acquisition of property, equipment and software

 

 

(503

)

 

 

(456

)

Acquisition of businesses, net of cash acquired

 

 

(1,012

)

 

 

(994

)

Purchases of marketable securities, net

 

 

(4

)

 

 

(9

)

Investments in unconsolidated affiliates, net of payments received

 

 

(14

)

 

 

(3

)

Proceeds from sale of equity securities

 

 

 

 

 

5

 

Other

 

 

4

 

 

 

1

 

Net cash used in investing activities

 

 

(1,529

)

 

 

(1,456

)

Financing activities:

 

 

 

 

Proceeds from issuance of debt

 

 

1,250

 

 

 

1,951

 

Payment of debt issuance costs

 

 

(5

)

 

 

(40

)

Repayment of debt and principal payments on finance leases

 

 

(86

)

 

 

(2,068

)

Proceeds from revolving credit facility

 

 

1,500

 

 

 

410

 

Repayment of revolving credit facility

 

 

(1,600

)

 

 

(300

)

Payments related to employee stock option plans

 

 

(70

)

 

 

(51

)

Repurchase of common stock

 

 

(1,103

)

 

 

(202

)

Acquisition of Quest’s non-controlling interest

 

 

 

 

 

(758

)

Contingent consideration and deferred purchase price payments

 

 

(22

)

 

 

(39

)

Net cash used in financing activities

 

 

(136

)

 

 

(1,097

)

Effect of foreign currency exchange rate changes on cash

 

 

(127

)

 

 

(41

)

Decrease in cash and cash equivalents

 

 

(92

)

 

 

(344

)

Cash and cash equivalents at beginning of period

 

 

1,366

 

 

 

1,814

 

Cash and cash equivalents at end of period

 

$

1,274

 

 

$

1,470

 

Contacts

Nick Childs, IQVIA Investor Relations (nicholas.childs@iqvia.com)

+1.973.316.3828

Read full story here